Condition 1: Multiple sclerosis. Condition 2: Major depressive disorder. Multiple sclerosis Major depressive disorder, single episode
Conditions
Interventions
Intervention 1: Intervention group: the intervention group, participants will receive a single daily dose of 25 mg of agomelatine orally, along with 50 mg of sertraline (or 20 mg of citalopram) admini
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Definitive diagnosis of multiple sclerosis is established through consultation with a neurologist based on the McDonald criteria Absence of relapse episodes one month prior to the initiation of the study. Expression of willingness to participate in the study. Diagnosis of major depressive disorder based on the assessment of a psychiatrist. Absence of other diseases such as chronic illnesses, renal disorders, or musculoskeletal conditions. No history of addiction to alcohol, illicit drugs, or psychoactive substances. Absence of pregnancy and lactation. No presence of other major psychiatric disorders aside from major depressive disorder.
Exclusion criteria
Exclusion criteria: Lack of patient cooperation in completing the questionnaire. Noncompliance with the regular administration of medication. Patient withdrawal from continued participation in the study. Patient's pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The Hamilton Depression Rating Scale (HDRS) score, with a score of less than or equal to 7, is defined as a response to treatment. Timepoint: At the beginning of the study, one month after the initiation of the intervention, and three months after the commencement of the intervention. Method of measurement: HDRS: Hamilton Depression Rating Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| MSIS: Multiple Sclerosis Impact Scale;. Timepoint: ?? ?????? ??????? ????? ??? ?? ???? ?????? ? ?? ??? ?? ?? ???? ?????? ????? ?? ????. Method of measurement: MSIS: Multiple Sclerosis Impact Scale;.;FSFI: Female Sexual Function Index;. Timepoint: At the beginning of the study, one month after the initiation of the intervention, and three months after the commencement of the intervention. Method of measurement: FSFI: Female Sexual Function Index.;IIEF: International Index of Erectile Function. Timepoint: At the beginning of the study, one month after the initiation of the intervention, and three months after the commencement of the intervention. Method of measurement: IIEF: International Index of Erectile Function. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHamid eslami
Mashhad University of Medical Sciences
Outcome results
None listed